David S Hong
Stanford University · ECOG-ACRIN Cancer Research Group · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David S Hong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07155707 · Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical SettingsStanford University · recruiting · Anxiety, Mood Disorders · principal investigator
- Ph2NCT06390852 · Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- N/ANCT06364137 · Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical SettingsStanford University · completed · Anxiety Disorders, Mood Disorders · principal investigator
- Ph2NCT06360575 · Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- Ph2NCT06357975 · Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- Ph1NCT05722327 · Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal CancerM.D. Anderson Cancer Center · active not recruiting · Colon Cancer, Colorectal Cancer · principal investigator
- Ph2NCT04879121 · Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid TumorsM.D. Anderson Cancer Center · recruiting · Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT03290937 · Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerM.D. Anderson Cancer Center · completed · Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 · principal investigator
- Ph2NCT02983578 · Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerM.D. Anderson Cancer Center · active not recruiting · Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma · principal investigator
- Ph1NCT02942095 · Study of Ixazomib and Erlotinib in Solid TumorsM.D. Anderson Cancer Center · completed · Solid Tumors · principal investigator
- Ph1NCT02915172 · Lenvatinib and Capecitabine in Patients With Advanced MalignanciesM.D. Anderson Cancer Center · withdrawn · Advanced Cancer, Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage · principal investigator
- Ph1NCT02668770 · Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesM.D. Anderson Cancer Center · terminated · Advanced Cancers, Melanoma · principal investigator
- Ph2NCT02478320 · Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid TumorsM.D. Anderson Cancer Center · terminated · Advanced Cancers · principal investigator
- Ph1NCT01787500 · Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryM.D. Anderson Cancer Center · completed · BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT01744652 · Dasatinib and Crizotinib in Advanced CancerM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01738139 · Ipilimumab and Imatinib Mesylate in Advanced CancerM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 · principal investigator
- Ph1NCT01608139 · Study of Curcumin, Vorinostat, and SorafenibM.D. Anderson Cancer Center · withdrawn · Advanced Cancers · principal investigator
- Ph1NCT01454804 · Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01430572 · Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss PatientsM.D. Anderson Cancer Center · completed · Advanced Cancers, Solid Tumors · principal investigator
- Ph1NCT01201694 · Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)M.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01113476 · Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced MalignanciesM.D. Anderson Cancer Center · completed · Advanced Cancer · study chair
- Ph1NCT01087554 · Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced CancerM.D. Anderson Cancer Center · active not recruiting · Advanced Cancer · principal investigator
- Ph1NCT00955812 · STAT3 Inhibitor for Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumor · principal investigator
- Ph1NCT00554268 · Trial of PBI-05204 in Advanced Cancer PatientsM.D. Anderson Cancer Center · completed · Solid Tumors · principal investigator
- Ph1NCT00508807 · RTA 402 in Advanced Solid Tumors or Lymphoid MalignanciesM.D. Anderson Cancer Center · completed · Lymphoid Malignancies, Solid Tumors · principal investigator
- Ph1NCT00431054 · Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian CancerM.D. Anderson Cancer Center · completed · Ovarian Cancer · principal investigator
- Ph1NCT00429234 · Gemcitabine and Dasatinib in Advanced Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Engagement and clinical impact of the Teleo virtual therapy platform in clinical settingsR42MH136878 · NIMH · MAINSQUARE CO · fiscal years 2024 to 2026 · $1,044,386 awarded in 2026Grant number is on one of their registry trials
- Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $476,200 awarded in 2026Same name and institution; not confirmed by an ID
- Research Training for Child Psychiatry and NeurodevelopmentT32MH019908 · NIMH · STANFORD UNIVERSITY · fiscal years 2026 · $344,085 awarded in 2026Same name and institution; not confirmed by an ID
- 12 Clinical and Translational Research CenterP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2025 · $379,325 awarded in 2025Grant number is on one of their registry trials
- Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted TherapyR01CA242565 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2025 · $218,645 awarded in 2025Same name and institution; not confirmed by an ID
- Sex hormone effects on neurodevelopment: Controlled puberty in transgender adolescentsR01MH115349 · NIMH · STANFORD UNIVERSITY · fiscal years 2018 to 2023 · $707,054 awarded in 2023Same name and institution; not confirmed by an ID
- Therapeutic Strategies for Patients With BRAF Mutant Colorectal CancerR01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2014 to 2018 · $332,000 awarded in 2018Grant number is on one of their registry trials
- Neuroanatomical substrates of cognition in mosaic Turner syndromeK23MH097120 · NIMH · STANFORD UNIVERSITY · fiscal years 2012 to 2015 · $181,410 awarded in 2015Same name and institution; not confirmed by an ID
- Mechanisms of B Cell Responses to a Novel Adjuvant for Influenza VaccineK08AI079269 · NIAID · STANFORD UNIVERSITY · fiscal years 2008 to 2012 · $130,599 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:55 UTC. The ranking covers the 200 most relevant of 163 PubMed records, and a shared surname and initials can bring in a namesake. All 163 on PubMed
- 2,232 citationsRCR 80.0
- 1,869 citationsRCR 67.8
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol · 2020856 citationsRCR 36.6
- Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.Br J Cancer · 2020835 citationsRCR 42.2
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.Invest New Drugs · 2017737 citationsRCR 27.6
- Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.N Engl J Med · 2023466 citationsRCR 40.2
- Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.J Clin Oncol · 2011465 citationsRCR 11.1
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).J Clin Oncol · 2021295 citationsRCR 15.5